Jardiance's HFpEF data looks stronger, with the usual caveats about comparing the results of different trials, but as the two drugs have different mechanisms of action there could be scope for ...

JARDIANCE is likely to be ineffective in this setting based upon its mechanism of action. CONTRAINDICATIONS: Hypersensitivity to empagliflozin or any of the excipients in JARDIANCE, reactions such ...

Eli Lilly and Boehringer Ingelheim's blockbuster diabetes drug Jardiance (empagliflozin ... to focus on cardiovascular health—this action will provide physicians another tool to address heart ...